Defining co-related parameters between 'metabolic' flare and 'clinical', 'biochemical', and 'osteoblastic' flare and establishing guidelines for assessing response to treatment in cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 4, 2007, Pages 441-443

  Basu, Sandip ^a   Alavi, Abass ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; GONADORELIN AGONIST; MEDRONATE TECHNETIUM TC 99M; TAMOXIFEN;

BLADDER NECK STENOSIS; BONE PAIN; BREAST CANCER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CARDIOVASCULAR RISK; DISEASE EXACERBATION; EDITORIAL; ERYTHEMA; HORMONAL THERAPY; HUMAN; METABOLISM; PAIN; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; SIDE EFFECT; SPINAL CORD COMPRESSION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; ARTIFACTS; FLUORODEOXYGLUCOSE F18; HUMANS; INFLAMMATION; NEOPLASMS; OSTEOBLASTS; POSITRON-EMISSION TOMOGRAPHY; PRACTICE GUIDELINES; PROGNOSIS; RADIOPHARMACEUTICALS; RADIOTHERAPY; TIME FACTORS; TREATMENT OUTCOME;

EID: 33947236746     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0264-6     Document Type: Editorial

References (19)

1. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;3513:1773-82.
2. Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 2005;46 6:983-95.
3. Kostakoglu L, Goldsmith SJ. PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. J Nucl Med 2004;45:56-68.
4. Basu S, Nair N. Is it time to incorporate quantitative functional imaging data, FDG PET in particular, into the response evaluation criteria in solid tumours? Nucl Med Commun 2006;27 5:413-6.
5. Dehdashti F, Flanagan FL, Mortimer JE, Katzenellenbogen JA, Welch MJ, Siegel BA. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 1999;26 1:51-6.
6. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 2001;1911:2797-803.
7. Biersack HJ, Bender H, Palmedo H. FDG-PET in monitoring therapy of breast cancer. Eur J Nucl Med Mol Imaging 2004;31 Suppl 1:S112-7.
8. Coleman RE, Mashiter G, Whitaker KB, Moss DW, Rubens RD, Fogelman I. Bone scan flare predicts successful systematic therapy for bone metastases [abstract]. J Nucl Med 1988;29:1354-9.
9. Vogel CL, Schoenfelder J, Shemano I, Hayes DF, Gams RA. Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol 1995;135:1123-8.
10. Tarle M, Kovacic K, Strelkov-Alfirevic A. Correlation between bone scans and serum levels of osteocalcin, prostate-specific antigen, and prostatic acid phosphatase in monitoring patients with disseminated cancer of the prostate. Prostate 1989;153:211-9.
11. Koizumi M, Matsumoto S, Takahashi S, Yamashita T, Ogata E. Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer. Clin Nucl Med 1999;24 1:15-20.
12. 18F-fluoride ion PET bone scanning. AJR Am J Roentgenol 2006;1866:1783-6.
13. Shimizu N, Masud H, Yamanaka H, Oriuchi N, Inoue T, Endo K. Fluorodeoxyglucose positron emission tomography scan of prostate cancer bone metastases with flare reaction after endocrine therapy. J Urol 1999;161:608-9.
14. Kuhn JM, Billebaud T, Navratil H, Moulonguet A, Fiet J, Grise P, et al. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med 1989;321:413-6.
15. Kahan A, Delreiu F, Amor B, Chiche R, Steg A. Disease flare induced by D-Trp6-LHRH analogue in patients with metastatic prostatic cancer. Lancet 1984;1:971-2.
16. Agarwal DK, Costello AJ, Peters J, Sikaris K, Crowe H. Differential response of prostate specific antigen to testosterone surge after luteinizing hormone-releasing hormone analogue in prostate cancer and benign prostatic hypertrophy. BJU Int 2000;85:690-5.
17. Bubley GJ. Is the flare clinically significant? Urology 2001;58 Supplement 2A:5-9.
18. Thompson IM, Zeidman EJ, Rodriguez FR. Sudden death due to disease flares with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. J Urol 1990;144 6:1479-80.
19. Plotkin D, Lechner JJ, Jung WE, Rosen PJ. Tamoxifen flare in advanced breast cancer. JAMA 1978;240:2644-6.